Rewalk Robotics (RWLK) received a Buy rating and a $9 price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The company’s shares closed on Friday at $3.38, close to its 52-week low of $2.46.
According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.9% and a 28.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.
Rewalk Robotics has an analyst consensus of Moderate Buy, with a price target consensus of $9.
See today’s analyst top recommended stocks >>
Based on Rewalk Robotics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.59 million. In comparison, last year the company had a GAAP net loss of $5.8 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ReWalk Robotics Ltd. engages in the design, development and marketing of wearable robotic exoskeletons. Its exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. The firm’s systems include ReWalk Rehabilitation and ReWalk Personal 6.0.
